A5004022181- Epilepsy research and treatment
- Migraine and Headache Studies
- Neurological disorders and treatments
- Trigeminal Neuralgia and Treatments
- Neurological Disorders and Treatments
- EEG and Brain-Computer Interfaces
- Sympathectomy and Hyperhidrosis Treatments
- Advanced MRI Techniques and Applications
- Cerebrospinal fluid and hydrocephalus
- Biochemical effects in animals
- Olfactory and Sensory Function Studies
- Neuroscience and Neuropharmacology Research
- Genetic Neurodegenerative Diseases
- Cardiac electrophysiology and arrhythmias
- Functional Brain Connectivity Studies
- Head and Neck Surgical Oncology
- Neuroscience and Neural Engineering
- Glycogen Storage Diseases and Myoclonus
- Ophthalmology and Eye Disorders
- Fetal and Pediatric Neurological Disorders
- Facial Nerve Paralysis Treatment and Research
- Neurobiology of Language and Bilingualism
- Pharmacological Effects and Toxicity Studies
Nagoya University
2022-2025
Mesial temporal lobe epilepsy (MTLE) is associated with disruptions in the temporo-amygdala-orbitofrontal (TAO) network, a key component of limbic system. We aimed to investigate TAO network alterations patients MTLE using magnetoencephalography (MEG), which overcomes susceptibility artifacts that limit functional MRI analysis orbitofrontal cortex. Nine seizure-free post-temporal lobectomy and nine age- sex-matched healthy controls were recruited. Preoperative MEG data collected segmented...
Background/Objectives: Lasmiditan is a newly developed drug for the acute treatment of migraine attacks, but factors associated with its efficacy remain unclear. This study aimed to confirm lasmiditan started at 50 mg under various dosing conditions and identify efficacy. Methods: There were four reasons prescribing lasmiditan: add-on triptan, ineffectiveness side effects triptan contraindicated. was dose mg. Efficacy defined as disappearance headache or 50% greater reduction in intensity...
Abstract Objective Patients with epilepsy have high risk of experiencing uncommon causes death. This study aimed to evaluate patients who underwent unusual deaths related and identify factors that may contribute these also include sudden unexpected death in (SUDEP). Methods We analyzed 5291 cases which a postmortem imaging (PMI) was performed using plane CT, because an unexplained A rapid troponin T assay peripheral blood samples. Clinical information including the cause suspected by...
Magnetic resonance-guided focused ultrasound (MRgFUS) thalamotomy is an effective treatment for essential tremor (ET). However, its long-term outcomes and prognostic factors remain unclear. This study aimed to retrospectively investigate 38 patients with ET who underwent MRgFUS were followed up >2 years. The improvement in was evaluated using the Clinical Rating Scale Tremor (CRST). Adverse events documented, correlations factors, such as skull density ratio (SDR), maximum mean temperature...
Abstract Background Abrupt discontinuation of overused medications is the gold standard treatment for medication overuse headache (MOH), but difficult to maintain. In this study, aim was evaluate real-world clinical results anti-calcitonin gene-related peptide monoclonal antibody (CGRP-mAb) MOH migraine without abrupt drug and no hospitalization. Methods Patients with receiving naïve CGRP-mAb were enrolled. Data collected before starting injections (baseline) after each injection. The...
Background: Abrupt discontinuation of overused medications is standard treatment for medication overuse headache (MOH), but difficult to maintain. The aim was evaluate the real-world clinical results anti-calcitonin gene-related peptide monoclonal antibody (CGRP-mAb) MOH migraine without abrupt drug and no hospitalization. Methods: Data were collected before starting CGRP-mAb injections (baseline) after each injection. following items compared between baseline injection: monthly days (MHD),...
Abrupt discontinuation of overused medications is standard treatment for medication overuse headache (MOH), but difficult to maintain. The aim was evaluate the real-world clinical results anti-calcitonin gene-related peptide monoclonal antibody (CGRP-mAb) migraine with MOH without abrupt drug and no hospitalization.
Three anti-calcitonin gene-related peptide monoclonal antibodies (CGRP-mAbs) are available in Japan: galcanezumab, fremanezumab, and erenumab. Early-onset efficacy has been demonstrated for each CGRP-mAb comparison with placebo, but differences among the drugs unclear. Only galcanezumab requires 2 doses at initial injection. This study is a multicenter, open-label, randomized, two-group trial, consisting of random selection 6 consecutive injections, then discontinuation after injections. The...